Pharmacokinetic Properties of Phosphorothioate Oligonucleotides in Humans

  • J. M. Leeds
  • R. S. Geary
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 131)


The use of antisense molecules to inhibit the expression of disease-causing proteins represents a new paradigm in disease treatment. The molecular target for the antisense molecules, mRNA, is chemically and biologically well defined. This well-defined target is the same for all different possible therapeutic applications, whether the application is antiviral, anticancer, or anti-inflammatory. The specificity with which antisense molecules are capable of inhibiting gene expression, exemplified by the isozyme selectivity demonstrated by [Dean and Mckay 1994], has allowed entirely novel molecular targets to be explored for potential therapeutic applications. Thus antisense molecules have presented an opportunity to exploit a single target for multiple therapeutic indications as well as to explore the utility of inhibiting targets which traditional therapeutic agents could not specifically inhibit.


Pharmacokinetic Property Antisense Oligonucleotide Peak Plasma Concentration Genital Wart Continuous Intravenous Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agrawal S (1996) Antisense oligonucleotides: towards clinical trials. Trends Biotech 14:376–387CrossRefGoogle Scholar
  2. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A (1996) Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol 14:1320–1326PubMedGoogle Scholar
  3. Campbell JM, Bacon TA, Wickstrom E (1990) Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J Biochem Biophys Methods 20:259–267PubMedCrossRefGoogle Scholar
  4. Cossum PA, Sasmor H, Dellinger D, Troung L, Cummins L, Owens SR, Markham PM, Shea JP, Crooke S (1993) Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181–1190PubMedGoogle Scholar
  5. Cowsert LM, Fox MC, Zon G, Mirabelli CK (1993) In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus:potential treatment for genital warts. Antimicrob Agents Chemother 37:171–177PubMedCrossRefGoogle Scholar
  6. Crooke ST, Bennett CF (1996) Progress in antisense oligonucleotide therapeutics.Annu Rev Pharmacol Toxicol 36:107–129Google Scholar
  7. Crooke ST, Grillone LR, Tendolkar A, Garrett A, Fratkin MJ, Leeds J, Barr WH (1994) A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts. Clin Pharmacol Ther 56:641–646PubMedCrossRefGoogle Scholar
  8. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL, Griffey RH (1996) Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 277:923–937PubMedGoogle Scholar
  9. Dean NM, McKay R (1994) Inhibition of protein kinase C-a expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91:11762–11766PubMedCrossRefGoogle Scholar
  10. Gaus H, Owens SR, Winniman M, Cooper S, Cummins LL. (1997) On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 69(3):313–319PubMedCrossRefGoogle Scholar
  11. Geary RS, Leeds JM, Shanahan W, Glover J, Pribble J, Truong L, Fitchett J, Burckin T, Nicklin P, Philips J, Levin AA (1996) Sequence independent plasma and tissue pharmacokinetics for 3 antisense phosphorothioate oligonucleotides: mouse to man. Pharm Res 13:53–95Google Scholar
  12. Geary RS, Leeds JM, Henry SP, Monteith D, Truong L, Fitchett J, Burckin T, Levin AA (1997) Pharmacokinetic properties of phosphorothioate oligonucleotides. In: Cook PD, Manoharan M (eds) Nucleosides and nucleotides. Marcel Decker, New York (in press)Google Scholar
  13. Glover JM, Leeds JM, Mant TGK, Amin D, Kisner DL, Zuckerman J, Geary RS, Levin AA, Shanahan WR (in press) Phase 1 safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp TherGoogle Scholar
  14. Hoke GD, Draper K, Freier SM, Gonzalez C, Driver VB, Zounes MC, Ecker DJ (1991) Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res 19:5743–5748PubMedCrossRefGoogle Scholar
  15. Lebedev AV, Raynaud E, M Beck T, Jaeger JA, Brown BD, Cunningham D, Webb A, McCampbell E, Riley T, Judson I, Woodle MC (1997) Anti-BCL2 phosphorothioate G3139 clinical pharmacology: plasma levels during continuous subcutaneous infusion by HPLC assay. In: Cook PD, Manoharan M (eds) Nucleosides and nucleotides. Marcel Decker, New York (in press)Google Scholar
  16. Leeds JM, Graham MJ, Truong, Cummins LL (1996) Quantitation of phos-phorothioate oligonucleotides in human plasma. Anal Biochem 235:36–43PubMedCrossRefGoogle Scholar
  17. Leeds JM, Geary RS, Henry SP, Glover J, Shanahan W, Fitchett J, Burckin T, Truong L, Levin AA (1997) Pharmacokinetic properties of phosphorothioate oligonucleotides. In: Cook PD, Manoharan M (eds) Nucleosides and nucleotides. Marcel Decker, New York (in press)Google Scholar
  18. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med 2:668–675PubMedCrossRefGoogle Scholar
  19. Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL (1994) Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and phosphorothioate. Mol Pharmacol 45:932–943PubMedGoogle Scholar
  20. Stein CA, Subasinghe C, Shinozuka K, Cohen JS (1988) Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 16:3209–3221PubMedCrossRefGoogle Scholar
  21. Wickstrom E (1986) Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 13:97–102PubMedCrossRefGoogle Scholar
  22. Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin R, Schechter PJ, Agrawal S, Diasio RB (1995) Pharmacokinetics of an antihuman immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther 58(1):45–53CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • J. M. Leeds
  • R. S. Geary

There are no affiliations available

Personalised recommendations